Laird Norton Wetherby Wealth Management LLC Increases Stock Position in Astrazeneca Plc $AZN

Laird Norton Wetherby Wealth Management LLC lifted its position in shares of Astrazeneca Plc (NYSE:AZN) by 6.0% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 76,106 shares of the company’s stock after buying an additional 4,332 shares during the period. Laird Norton Wetherby Wealth Management LLC’s holdings in Astrazeneca were worth $5,839,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in AZN. Rakuten Investment Management Inc. acquired a new position in Astrazeneca in the third quarter valued at $31,000. JPL Wealth Management LLC acquired a new stake in Astrazeneca during the third quarter worth about $35,000. E Fund Management Hong Kong Co. Ltd. raised its holdings in shares of Astrazeneca by 144.0% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 466 shares of the company’s stock worth $36,000 after purchasing an additional 275 shares during the period. VSM Wealth Advisory LLC purchased a new position in shares of Astrazeneca in the 2nd quarter worth about $33,000. Finally, FSA Wealth Management LLC lifted its stake in shares of Astrazeneca by 376.0% in the 2nd quarter. FSA Wealth Management LLC now owns 476 shares of the company’s stock valued at $33,000 after purchasing an additional 376 shares in the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

AZN has been the subject of a number of research analyst reports. Morgan Stanley reissued an “overweight” rating and set a $103.00 target price on shares of Astrazeneca in a research report on Wednesday, December 3rd. TD Cowen reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Tuesday, December 9th. HSBC reiterated a “buy” rating and set a $108.00 price objective on shares of Astrazeneca in a research note on Wednesday, December 10th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a research note on Friday, February 6th. Finally, Barclays restated an “overweight” rating on shares of Astrazeneca in a report on Tuesday, January 6th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $95.75.

Astrazeneca Trading Up 1.1%

Shares of NYSE:AZN opened at $191.99 on Tuesday. The stock has a market cap of $297.75 billion, a P/E ratio of 20.73, a P/E/G ratio of 1.43 and a beta of 0.32. The company has a current ratio of 0.94, a quick ratio of 0.72 and a debt-to-equity ratio of 0.51. Astrazeneca Plc has a one year low of $122.48 and a one year high of $212.71.

Astrazeneca Announces Dividend

The company also recently disclosed a dividend, which will be paid on Monday, March 23rd. Stockholders of record on Friday, February 20th will be paid a dividend of $1.595 per share. The ex-dividend date is Friday, February 20th. This represents a dividend yield of 156.0%. Astrazeneca’s dividend payout ratio (DPR) is currently 66.26%.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.